Evidence map›Paper›PMID 23429537›Full record

ArticleInfection and immunity2013

Overcoming allelic specificity by immunization with five allelic forms of Plasmodium falciparum apical membrane antigen 1.

Kazutoyo Miura, Raul Herrera, Ababacar Diouf, Hong Zhou, Jianbing Mu, Zonghui Hu, Nicholas J MacDonald, Karine Reiter, Vu Nguyen, Richard L Shimp and 4 more

Abstract read
In one paragraph

Article in Infection and immunity, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Antibodies Against theFrontiers in cellular and infection microbiology · 2021
    Article
  9. Article
  10. Sequence Analysis of Pvama-1 amongEthiopian journal of health sciences · 2020
    Article
  11. Article
  12. Article
  13. Immune Responses in Malaria.Cold Spring Harbor perspectives in medicine · 2017
    Review
  14. A malaria vaccine protectsNPJ vaccines · 2017
    Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Kazutoyo MiuraLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA. kmiura@niaid.nih.gov
Raul Herrera
Ababacar Diouf
Hong Zhou
Jianbing Mu
Zonghui Hu
Nicholas J MacDonald
Karine Reiter
Vu Nguyen
Richard L Shimp
Kavita Singh
David L Narum
Carole A Long
Louis H Miller

Funding

Malaria Parasite Receptors And Host Cell LigandsZIAAI000241 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI MILLER, LOUIS · 2009 to 2025
$15.3M
Host Immune Responses to Antigens of Malaria ParasitesZIAAI001020 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI LONG, CAROLE · 2009 to 2025
$13.6M
Intramural NIH HHS
6 · The paper itself

Abstract

Apical membrane antigen 1 (AMA1) is a leading vaccine candidate, but the allelic polymorphism is a stumbling block for vaccine development. We previously showed that a global set of AMA1 haplotypes could be grouped into six genetic populations. Using this information, six recombinant AMA1 proteins representing each population were produced. Rabbits were immunized with either a single recombinant AMA1 protein or mixtures of recombinant AMA1 proteins (mixtures of 4, 5, or 6 AMA1 proteins). Antibody levels were measured by enzyme-linked immunosorbent assay (ELISA), and purified IgG from each rabbit was used for growth inhibition assay (GIA) with 12 different clones of parasites (a total of 108 immunogen-parasite combinations). Levels of antibodies to all six AMA1 proteins were similar when the antibodies were tested against homologous antigens. When the percent inhibitions in GIA were plotted against the number of ELISA units measured with homologous AMA1, all data points followed a sigmoid curve, regardless of the immunogen. In homologous combinations, there were no differences in the percent inhibition between the single-allele and allele mixture groups. However, all allele mixture groups showed significantly higher percent inhibition than the single-allele groups in heterologous combinations. The 5-allele-mixture group showed significantly higher inhibition to heterologous parasites than the 4-allele-mixture group. On the other hand, there was no difference between the 5- and 6-allele-mixture groups. These data indicate that mixtures with a limited number of alleles may cover a majority of the parasite population. In addition, using the data from 72 immunogen-parasite combinations, we mathematically identified 13 amino acid polymorphic sites which significantly impact GIA activities. These results could be a foundation for the rational design of a future AMA1 vaccine.

Indexed as

AllelesAnimalsAntibodies, ProtozoanAntibody SpecificityAntigens, ProtozoanEnzyme-Linked Immunosorbent AssayImmunoglobulin GMalaria, FalciparumMalaria VaccinesMembrane ProteinsPlasmodium falciparumProtozoan ProteinsRabbitsRecombinant ProteinsAntibodies, ProtozoanAntigens, Protozoanapical membrane antigen I, PlasmodiumImmunoglobulin GMalaria VaccinesMembrane ProteinsProtozoan ProteinsRecombinant Proteins

Identifiers

PMID23429537
PMCPMC3648006

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.